Dirk M. Zahm

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl et al. · The Lancet Oncology · 2014 · 1K citations

Medicine, Oncology, Breast Oncology +12

Response-Guided Neoadjuvant Chemotherapy for Breast Cancer

Gϋnter von Minckwitz, Jens‐Uwe Blohmer, Serban Dan Costa et al. · Journal of Clinical Oncology · 2013 · 425 citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

Jens Huober, Gϋnter von Minckwitz, Carsten Denkert et al. · Breast Cancer Research and Treatment · 2010 · 294 citations

Medicine, Oncology, Pharmacology +17

<i>PIK3CA</i> Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

Sibylle Loibl, Gϋnter von Minckwitz, Andreas Schneeweiß et al. · Journal of Clinical Oncology · 2014 · 258 citations · Full text

Medicine, Cancer Biology, Oncology +17

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

Barbara Ingold Heppner, Michael Untch, Carsten Denkert et al. · Clinical Cancer Research · 2016 · 202 citations

Medicine, Immunology, Oncology +16